0001104659-22-104796.txt : 20220930
0001104659-22-104796.hdr.sgml : 20220930
20220930214913
ACCESSION NUMBER: 0001104659-22-104796
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220928
FILED AS OF DATE: 20220930
DATE AS OF CHANGE: 20220930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Salain Daniel
CENTRAL INDEX KEY: 0001824804
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31918
FILM NUMBER: 221285730
MAIL ADDRESS:
STREET 1: C/O GRAYBUG VISION, INC.
STREET 2: 275 SHORELINE DRIVE, SUITE 450
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000861838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043072298
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 4843481600
MAIL ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: HYBRIDON INC
DATE OF NAME CHANGE: 19951211
4
1
tm2227191-8_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-09-28
0
0000861838
IDERA PHARMACEUTICALS, INC.
IDRA
0001824804
Salain Daniel
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BLVD.
EXTON
PA
19341
0
1
0
0
Chief Operating Officer
Common Stock, par value $0.001
2022-09-28
4
A
0
2171214
A
2171214
D
Series Z Convertible Preferred Stock
2022-09-28
4
A
0
22810
A
Common Stock
22810000
22810
D
Pursuant to the Agreement and Plan of Merger by and between Idera Pharmaceuticals, Inc. ("Idera") and Aceragen, Inc. ("Aceragen"), dated September 28, 2022, Aceragen merged with and became a wholly-owned subsidiary of Idera (the "Merger"). Pursuant to the Merger, each issued and outstanding share of Aceragen common stock was converted into 2.6332 shares of common stock of Idera, par value $0.001 per share ("Common Stock") and 27.0005 shares of the Idera Series Z Non-Voting Convertible Preferred Stock, par value $0.01 ("Series Z Preferred Stock").
Contingent upon stockholder approval of the conversion of Series Z Preferred Stock into shares of Common Stock, each share of Series Z Preferred Stock is convertible into 1,000 shares of Common Stock, at any time at the option of the holder thereof, subject to certain limitations.
/s/ John J. Kirby, Attorney-in-Fact for Daniel Salain
2022-09-30